Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study
- 1 July 1995
- journal article
- clinical trial
- Published by Elsevier in Clinical Therapeutics
- Vol. 17 (4) , 680-685
- https://doi.org/10.1016/0149-2918(95)80044-1
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- A 5‐year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calciumEuropean Journal of Clinical Investigation, 1994
- Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: A dose-response studyCalcified Tissue International, 1994
- Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitoninJournal of Bone and Mineral Research, 1994
- Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosisThe American Journal of Medicine, 1993
- Prevention and treatment of osteoporosisThe Lancet, 1993
- Effect of salmon calcitonin nasal spray on bone mass in patients with high turnover osteoporosisOsteoporosis International, 1993
- Effects of continuous and cyclic nasal calcitonin administration in ovariectomized womenMaturitas, 1992
- Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.BMJ, 1992
- An effective regimen of intranasal salmon calcitonin in early postmenopausal bone lossCalcified Tissue International, 1992
- Discontinuous calcitonin treatment of established osteoporosis—effects of withdrawal of treatmentThe American Journal of Medicine, 1990